Drizalma Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. It is protected by 5 US drug patents filed from 2019 to 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 13, 2037. Details of Drizalma Sprinkle's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10959982 | Duloxetine sprinkles |
Apr, 2037
(11 years from now) | Active |
| US9839626 | Duloxetine sprinkles |
Apr, 2037
(11 years from now) | Active |
| US11202772 | Duloxetine sprinkles |
Apr, 2037
(11 years from now) | Active |
| US10413525 | Duloxetine sprinkles |
Apr, 2037
(11 years from now) | Active |
| US12171742 | Duloxetine sprinkles |
Apr, 2037
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Drizalma Sprinkle's patents.
Latest Legal Activities on Drizalma Sprinkle's Patents
Given below is the list of recent legal activities going on the following patents of Drizalma Sprinkle.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Mar, 2023 | US10413525 |
| Mail O.P. Petition Decision | 26 Apr, 2022 | US11202772 |
| Email Notification
Critical | 26 Apr, 2022 | US11202772 |
| Electronic Review
Critical | 26 Apr, 2022 | US11202772 |
| Mail-Petition Decision - Granted | 22 Apr, 2022 | US11202772 |
| Petition Decision - Granted
Critical | 21 Apr, 2022 | US11202772 |
| O.P. Petition Decision | 19 Apr, 2022 | US11202772 |
| Petition Entered | 11 Apr, 2022 | US11202772 |
| Electronic Review
Critical | 11 Mar, 2022 | US11202772 |
| Email Notification
Critical | 11 Mar, 2022 | US11202772 |
US patents provide insights into the exclusivity only within the United States, but
Drizalma Sprinkle is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Drizalma Sprinkle's family patents as well as insights into
ongoing legal events
on those patents.
Drizalma Sprinkle's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Drizalma Sprinkle's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 13, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Drizalma Sprinkle Generic API suppliers:
Duloxetine Hydrochloride is the generic name for the brand Drizalma Sprinkle. 23 different companies have already filed for the generic of Drizalma Sprinkle, with Breckenridge having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Drizalma Sprinkle's generic
Alternative Brands for Drizalma Sprinkle
There are several other brand drugs using the same active ingredient (Duloxetine Hydrochloride) as Drizalma Sprinkle. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Lilly |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Duloxetine Hydrochloride, Drizalma Sprinkle's active ingredient. Check the complete list of approved generic manufacturers for Drizalma Sprinkle
About Drizalma Sprinkle
Drizalma Sprinkle is a drug owned by Sun Pharmaceutical Industries Ltd. Drizalma Sprinkle uses Duloxetine Hydrochloride as an active ingredient. Drizalma Sprinkle was launched by Sun Pharm in 2019.
Approval Date:
Drizalma Sprinkle was approved by FDA for market use on 19 July, 2019.
Active Ingredient:
Drizalma Sprinkle uses Duloxetine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Duloxetine Hydrochloride ingredient
Dosage:
Drizalma Sprinkle is available in capsule, delayed rel pellets form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 40MG BASE | CAPSULE, DELAYED REL PELLETS | Prescription | ORAL |
| EQ 60MG BASE | CAPSULE, DELAYED REL PELLETS | Prescription | ORAL |
| EQ 20MG BASE | CAPSULE, DELAYED REL PELLETS | Prescription | ORAL |
| EQ 30MG BASE | CAPSULE, DELAYED REL PELLETS | Prescription | ORAL |